ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ANDEMBRY, reinforcing CSL ...

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA ...

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping out’. The world-class facility will ...

For additional photos, logos and other branding elements, visit Brand.csl.com and Create an Account in the External Users Only box.